Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYM NASDAQ:IVA NASDAQ:NBP NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$13.19-1.3%$10.91$1.19▼$13.69$756.41M0.09847,582 shs325,812 shsIVAInventiva$3.76+5.8%$4.65$2.85▼$7.98$775.79M0.68539,472 shs1.17 million shsNBPI-Mab$1.99+0.3%$1.92$1.46▼$6.79$229.56M1.48857,143 shs581,419 shsNVCTNuvectis Pharma$18.45-35.3%$11.86$5.55▼$29.27$490.07M-0.07124,273 shs1.90 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio+2.14%+9.69%+21.90%+95.04%+1,032.20%IVAInventiva+3.98%+1.14%-27.99%-35.98%+16.93%NBPI-Mab+20.73%+29.41%+7.61%-19.51%+197,999,900.00%NVCTNuvectis Pharma+4.93%+72.60%+192.62%+269.08%+277.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$13.19-1.3%$10.91$1.19▼$13.69$756.41M0.09847,582 shs325,812 shsIVAInventiva$3.76+5.8%$4.65$2.85▼$7.98$775.79M0.68539,472 shs1.17 million shsNBPI-Mab$1.99+0.3%$1.92$1.46▼$6.79$229.56M1.48857,143 shs581,419 shsNVCTNuvectis Pharma$18.45-35.3%$11.86$5.55▼$29.27$490.07M-0.07124,273 shs1.90 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio+2.14%+9.69%+21.90%+95.04%+1,032.20%IVAInventiva+3.98%+1.14%-27.99%-35.98%+16.93%NBPI-Mab+20.73%+29.41%+7.61%-19.51%+197,999,900.00%NVCTNuvectis Pharma+4.93%+72.60%+192.62%+269.08%+277.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.07Buy$21.7362.63% UpsideIVAInventiva 3.10Buy$16.56366.35% UpsideNBPI-Mab 2.00Hold$9.00354.55% UpsideNVCTNuvectis Pharma 2.00Hold$39.0036.70% UpsideCurrent Analyst Ratings BreakdownLatest NBP, NVCT, IVA, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/22/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $39.006/12/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $13.006/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/5/2026NVCTNuvectis Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/AIVAInventiva$4.48M164.48N/AN/A($0.22) per share-16.14NBPI-MabN/AN/AN/AN/A$2.00 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)IVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/AN/ANBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/ANVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)Latest NBP, NVCT, IVA, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A4/8/2026Q4 2025NBPI-MabN/A-$0.2990N/A-$0.2990N/AN/A3/30/2026Q4 2025IVAInventiva-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A27.8627.86IVAInventivaN/A3.163.16NBPI-MabN/A8.098.09NVCTNuvectis PharmaN/A2.272.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%IVAInventiva19.06%NBPI-Mab38.38%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio2.60%IVAInventiva32.00%NBPI-Mab22.10%NVCTNuvectis Pharma28.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio957.26 million55.77 millionN/AIVAInventiva100207.71 million141.24 millionNot OptionableNBPI-Mab380115.65 million90.09 millionN/ANVCTNuvectis Pharma826.53 million18.95 millionNot OptionableNBP, NVCT, IVA, and CLYM HeadlinesRecent News About These CompaniesNuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)10 minutes ago | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Sets New 1-Year High - Should You Buy?June 30 at 3:27 AM | americanbankingnews.comNuvectis Pharma Prices $100 Million Underwritten Public Offering of Common StockJune 29 at 10:50 PM | quiverquant.comQNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockJune 29 at 10:30 PM | globenewswire.comNuvectis Pharma Suspends Equity Offering Program Under AgreementJune 29 at 4:51 PM | tipranks.comNuvectis Pharma Announces Proposed Public Offering of Common StockJune 29 at 4:01 PM | globenewswire.comNuvectis Pharma (NASDAQ:NVCT) Stock Price Down 7.7% - Should You Sell?June 28 at 3:40 AM | americanbankingnews.comWhat Makes Nuvectis Pharma (NVCT) a New Buy StockJune 26, 2026 | zacks.comNuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar MarketsJune 23, 2026 | theglobeandmail.comNuvectis Pharma jumps 20% to 52-week high — here's why NVCT stock is trendingJune 23, 2026 | msn.comNuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)June 22, 2026 | finance.yahoo.comNuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks TranscriptJune 22, 2026 | seekingalpha.comNuvectis gains two experimental drugs in licensing deal with China's HaiscoJune 22, 2026 | reuters.comNuvectis Pharma Expands Pipeline with Exclusive Ex-China Rights to Haisco’s NXP100 and NXP200 Clinical-Stage CandidatesJune 22, 2026 | quiverquant.comQNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage ...June 22, 2026 | markets.businessinsider.comNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage CompoundsJune 22, 2026 | globenewswire.comNVCT Share News TodayJune 17, 2026 | uk.investing.comNuvectis Shareholders Approve Director Election and Auditor RatificationJune 12, 2026 | tipranks.comWall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a BetMay 25, 2026 | zacks.comNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 14, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 2026Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?By Nathan Reiff | June 16, 2026Before the IPO: 4 Companies That Rewarded Investors Who Got In EarlyBy Bridget Bennett | June 4, 2026USA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBy Peter Frank | June 22, 2026Carnival's Second Quarter: Is the Stock Still Complicated?By Peter Frank | June 25, 2026NBP, NVCT, IVA, and CLYM Company DescriptionsClimb Bio NASDAQ:CLYM$13.18 -0.18 (-1.31%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Inventiva NASDAQ:IVA$3.76 +0.21 (+5.77%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.I-Mab NASDAQ:NBP$1.98 +0.01 (+0.25%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Nuvectis Pharma NASDAQ:NVCT$18.45 -10.08 (-35.32%) As of 12:54 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Wall Street Still Sees Massive Upside for AeroVironment Stock Manchester United’s Stock Rally Faces a Test Beyond Old Trafford Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying Volkswagen’s 16-Year Low Masks a Massive Margin Engine Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat Overclocking Qualcomm: Rewiring the AI Compute Market SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
